CoChat

Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative

Open access
Gong, Zhihong, Aragaki, Aaron K., Chlebowski, Rowan T., Manson, JoAnn E., Rohan, Thomas E., Chen, Chu, Vitolins, Mara Z., Tinker, Lesley F., LeBlanc, Erin S., Kuller, Lewis H., Hou, Lifang, LaMonte, Michael J., Luo, Juhua, Wactawski‐Wende, Jean · 2016 · International Journal of Cancer
Cited by 50

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Findings from studies of metformin use with risk of cancer incidence and outcome provide mixed results; with few studies examined associations by recency of diabetes diagnosis or duration of medication use. Thus, in the Women's Health Initiative, we examined these associations and further explored whether associations differ by recency of diabetes and duration of metformin use. Cox regression models were used to estimate hazard ratios (HR) and their 95% confidence intervals. Diabetes was associated with higher risk of total invasive cancer (HR, 1.13; p < 0.001) and of several site‐specific cancers (HR, 1.2–1.4, and up to over twofold). Diabetes was also associated with higher risk of death from cancer (HR, 1.46; p < 0.001). There was no overall difference in cancer incidence by diabetes therapy (p = 0.66). However, there was a lower risk of death from cancer for metformin users, compared to users of other medications, relative to women without diabetes, overall (HRs, 1.08 vs. 1.45; p = 0.007) and for breast cancer (HRs, 0.50 vs. 1.29; p = 0.05). Results also suggested that lower cancer risk associated with metformin may be evident only for a longer duration of use in certain cancer sites or subgroup populations. We provide further evidence that postmenopausal women with diabetes are at higher risk of invasive cancer and cancer death. Metformin users, particularly long‐term users, may be at lower risk of developing certain cancers and dying from cancer, compared to users of other anti‐diabetes medications. Future studies are needed to determine the long‐term effect of metformin in cancer risk and survival from cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.29944

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 50

Metadata

Authors
Gong, Z., Aragaki, A. K., Chlebowski, R. T., Manson, J. E., Rohan, T. E., Chen, C., Vitolins, M. Z., Tinker, L. F., LeBlanc, E. S., Kuller, L. H., Hou, L., LaMonte, M. J., Luo, J., & Wactawski‐Wende, J.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2015-12-15
Volume
138
Issue
8
Pages
1915-1927
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2182067229
Cited by
50
References
16
FWCI
2.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.